RT Journal Article SR Electronic T1 Atypical depression shares genetic predisposition with immuno-metabolic traits: a population-based study JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2020.02.18.20024091 DO 10.1101/2020.02.18.20024091 A1 Isabella Badini A1 Jonathan R.I. Coleman A1 Saskia P. Hagenaars A1 Matthew Hotopf A1 Gerome Breen A1 Cathryn M. Lewis A1 Chiara Fabbri YR 2020 UL http://medrxiv.org/content/early/2020/02/23/2020.02.18.20024091.abstract AB Background Depression is a highly prevalent and heterogenous disorder. Clinical heterogeneity may reflect different underlying biological mechanisms. This study aims to determine whether atypical depression shows higher heritability and different degree of overlap with polygenic risk for cardio- and immuno- metabolic traits than non-atypical depression.Methods Data included 30,069 individuals from the UK Biobank who met criteria for lifetime major depression. Participants reporting both hypersomnia and weight gain were classified as atypical cases (N = 1,854), and the others as non-atypical cases (N = 28,215). Non-atypical cases were further classified as typical depression (i.e. insomnia and weight loss; N = 10,142). Polygenic risk scores (PRS) for 21 traits were generated using genome-wide summary statistics (Bonferroni corrected p=2.2×10−4). Single nucleotide polymorphism (SNP)-based heritability of atypical and typical depression was estimated.Results Atypical depression had a higher polygenic risk for BMI (OR=1.20, [1.15-1.26], p=2.37e-14), and C-reactive protein (OR=1.11, [1.06-1.17], p=8.86e-14) vs. non-atypical cases. Leptin PRS was very close to the significance threshold (p=4.13e-04), but the effect disappeared when considering GWAS summary statistics of leptin adjusted for BMI. PRS for daily alcohol use was inversely associated with atypical depression (OR=0.88, [0.84-0.93], p=1.04e-05) vs. non-atypical depression. SNP-based heritability on the liability scale was not significantly different between atypical and typical depression (5.2% and 4.5%, respectively).Conclusions Atypical depression shows evidence of distinct genetic predisposition to immune-metabolic traits in line with the previous literature. These genetic signals suggest that biological targets including cardiometabolic or immune pathways may be germane to therapies in individuals with atypical depression.Competing Interest StatementCathryn Lewis is a member of the Scientific Advisory Board of Myriad Neurosciences. Matthew Hotopf is principal investigator of RADAR-CNS (funded by European Commission, Janssen, Biogen, UCB, MSD and Lundbeck).Funding StatementThis research was supported by the UK Medical Research Council (MR/N015746/1). This paper represents independent research part-funded by the National Institute for Health Research (NIHR) Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King’s College London. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care. The authors acknowledge use of the research computing facility at King’s College London, Rosalind (https://rosalind.kcl.ac.uk), which is delivered in partnership with the National Institute for Health Research (NIHR) Biomedical Research Centres at South London & Maudsley and Guy’s & St. Thomas’ NHS Foundation Trusts, and part-funded by capital equipment grants from the Maudsley Charity (award 980) and Guy’s & St. Thomas’ Charity (TR130505).Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesUK Biobank data was accessed under application 18177.